Crossmark

Mesothelin as a target for cervical cancer therapy

Crossref DOI link: https://doi.org/10.1007/s00404-018-4933-z

Published Online: 2018-10-15

Published Print: 2019-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jöhrens, Korinna https://orcid.org/0000-0001-5934-544X
Lazzerini, Lea https://orcid.org/0000-0002-5370-8163
Barinoff, Jana https://orcid.org/0000-0003-3813-9270
Sehouli, Jalid https://orcid.org/0000-0002-5963-6623
Cichon, Guenter https://orcid.org/0000-0002-4500-8108
Funding

Funding for this research was provided by:

Bundesministerium für Bildung und Forschung (03V0347)

Bayer CropScience
License Information

Text and Data Mining valid from 2018-10-15
More Information

Article History

Received: 6 July 2018

Accepted: 4 October 2018

First Online: 15 October 2018

Compliance with ethical standards

:

: Dr. Cichon received grant monies from Bayer AG. Prof. Sehouli receives funding for studies in ovarian cancer and serves on the Advisory Board as a consultant for Bayer. The other authors have no conflict of interest to declare.